首页> 美国卫生研究院文献>Drugs in RD >Comparison of Dissolution Profiles and Serum Concentrations of Two Lamotrigine Tablet Formulations
【2h】

Comparison of Dissolution Profiles and Serum Concentrations of Two Lamotrigine Tablet Formulations

机译:两种拉莫三嗪片剂的溶出曲线和血清浓度的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective: The aim of this study was to investigate the extent of variations in lamotrigine serum concentrations between two immediate-release tablet formulations. Data were compared with in vitro difference and similarity tests on dissolution profiles of the two formulations.>Methods: Dissolution characteristics of formulations A (reference) and B (test) were evaluated at three points spanning the physiologic pH range (pH 1.2, pH 4.5, pH 6.8). A model-independent approach of difference (f1) and similarity (f2) tests were applied to dissolution data. A clinical study was performed with 16 patients who were divided into two groups — one group received formulation A (n=9) and the other received formulation B (n=7). Lamotrigine steady-state concentrations were determined by high-performance liquid chromatography on a reverse-phase column.>Results: There were no statistically significant differences in lamotrigine serum concentrations between the two groups, although formulation B had slightly higher mean concentration values (formulation A: 3.97±4.1 μg/mL; formulation B: 5.78±2.7 μg/mL). Dissolution profiles of the two formulations were similar in the pH 1.2 dissolution medium; however, the dissolution profiles of formulation B were outside the dissolution limit (≥85% at 15 minutes) in the pH 4.5 and 6.8 dissolution media.>Conclusions: No significant changes in the serum concentrations of lamotrigine were seen between the two investigated formulations. There is no evidence to suggest that the differences in dissolution profiles at pH 4.5 and pH 6.8 affect the therapeutic efficacy of the formulations. It is evident that the doses of test formulation given to the patients were higher as a consequence of common assumption that generic products have a lower absorption rate, which is proven unnecessary in this study. This investigation was a pilot study and thus further investigations with a larger sample size are necessary to determine if there is a connection between dissolution profiles and the therapeutic effect of investigated formulations.
机译:>目的:该研究的目的是研究两种速释片剂之间拉莫三嗪血清浓度的变化程度。将数据与两种配方的溶出曲线的体外差异和相似性测试进行比较。>方法:在跨越生理pH范围的三个点上评估了配方A(参考)和B(测试)的溶出特性(pH 1.2,pH 4.5,pH 6.8)。将与模型无关的差异(f1)和相似性(f2)测试方法应用于溶出度数据。对16名患者进行了一项临床研究,将其分为两组-一组接受制剂A(n = 9),另一组接受制剂B(n = 7)。通过反相色谱柱上的高效液相色谱法测定拉莫三嗪的稳态浓度。>结果:两组之间拉莫三嗪的血清浓度没有统计学上的显着差异,尽管制剂B的含量略高平均浓度值(制剂A:3.97±4.1μg/ mL;制剂B:5.78±2.7μg/ mL)。在pH 1.2溶出介质中,两种制剂的溶出曲线相似。但是,制剂B在pH 4.5和6.8溶出介质中的溶出曲线超出溶出极限(15分钟时≥85%)。>结论:拉莫三嗪的血清浓度未见明显变化在两个调查的公式之间。没有证据表明pH 4.5和pH 6.8时溶出度的差异会影响制剂的治疗功效。显然,由于一般假设通用产品具有较低的吸收率,因此给予患者的测试制剂剂量更高,这在本研究中被证明是不必要的。这项研究是一项试点研究,因此需要进行更大样本量的进一步研究,以确定溶出曲线与所研究制剂的治疗效果之间是否存在联系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号